Biomarker Testing Services Market Size, Share & Trends Report

Biomarker Testing Services Market Size, Share & Trends Analysis Report By Service (Biomarker Assay Development & Validation, Flow Cytometry), By Application (Oncology, Drug Discovery & Development), By Type, By End-use,By Region, And Segment Forecasts, 2025 - 2030

Report ID: GVR-4-68039-986-1
Number of Report Pages: 150
Format: PDF

Historical Range: 2018 - 2024
Forecast Period: 2025 - 2030
Industry: Healthcare

Market Segmentation

Biomarker Testing Service Outlook (Revenue in USD Million, 2018 - 2030)
- Biomarker Assay Development & Validation
- Flow Cytometry
- Others
Biomarker Testing Services Application Outlook (Revenue in USD Million, 2018 - 2030)
- Oncology
- Drug Discovery & Development
- Others
Biomarker Testing Services Type Outlook (Revenue in USD Million, 2018 - 2030)
- Molecular Biomarkers
- Cellular Biomarkers
Biomarker Testing Services End Use Outlook (Revenue in USD Million, 2018 - 2030)
- Pharmaceutical and Biotechnology Companies
- Research Institutes
- CROs
Biomarker Testing Services Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Service Outlook (Revenue in USD Million, 2018 - 2030)
    - Biomarker Assay Development & Validation
    - Flow Cytometry
    - Others
  - North America Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology
    - Drug Discovery & Development
    - Others
  - North America Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Molecular Biomarkers
    - Cellular Biomarkers
    - North America End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Pharmaceutical and Biotechnology Companies
    - Research Institutes
    - CROs
  - U.S.
    - U.S. Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - U.S. Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - U.S. Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - U.S. End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Canada
    - Canada Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Canada Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Canada Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Canada End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Mexico
    - Mexico Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Mexico Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Mexico Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Mexico End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
- Europe
  - Europe Service Outlook (Revenue in USD Million, 2018 - 2030)
    - Biomarker Assay Development & Validation
    - Flow Cytometry
    - Others
  - Europe Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology
    - Drug Discovery & Development
    - Others
  - Europe Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Molecular Biomarkers
    - Cellular Biomarkers
  - Europe End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Pharmaceutical and Biotechnology Companies
    - Research Institutes
    - CROs
  - UK
    - UK Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - UK Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - UK Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - UK End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Germany
    - Germany Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Germany Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Germany Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Germany End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - France
    - France Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - France Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - France Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - France End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Italy
    - Italy Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Italy Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Italy Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Italy End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Spain
    - Spain Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Spain Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Spain Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Spain End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Denmark
    - Denmark Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Denmark Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Denmark Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Denmark End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Sweden
    - Sweden Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Sweden Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Sweden Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Sweden End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Norway
    - Norway Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Norway Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Norway Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Norway End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
- Asia Pacific
  - Asia Pacific Service Outlook (Revenue in USD Million, 2018 - 2030)
    - Biomarker Assay Development & Validation
    - Flow Cytometry
    - Others
  - Asia Pacific Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology
    - Drug Discovery & Development
    - Others
  - Asia Pacific Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Molecular Biomarkers
    - Cellular Biomarkers
  - Asia Pacific End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Pharmaceutical and Biotechnology Companies
    - Research Institutes
    - CROs
  - Japan
    - Japan Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Japan Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Japan Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Japan End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - China
    - China Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - China Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - China Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - China End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - India
    - India Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - India Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - India Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - India End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - South Korea
    - South Korea Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - South Korea Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - South Korea Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - South Korea End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Australia
    - Australia Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Australia Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Australia Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Australia End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Thailand
    - Thailand Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Thailand Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Thailand Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Thailand End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Indonesia
    - Indonesia Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Indonesia Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Indonesia Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Indonesia End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Malaysia
    - Malaysia Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Malaysia Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Malaysia Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Malaysia End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Singapore
    - Singapore Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Singapore Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Singapore Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Singapore End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Taiwan
    - Taiwan Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Taiwan Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Taiwan Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Taiwan End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
- Latin America
  - Latin America Service Outlook (Revenue in USD Million, 2018 - 2030)
    - Biomarker Assay Development & Validation
    - Flow Cytometry
    - Others
  - Latin America Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology
    - Drug Discovery & Development
    - Others
  - Latin America Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Molecular Biomarkers
    - Cellular Biomarkers
  - Latin America End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Pharmaceutical and Biotechnology Companies
    - Research Institutes
    - CROs
  - Brazil
    - Brazil Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Brazil Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Brazil Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Brazil End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Argentina
    - Argentina Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Argentina Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Argentina Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Argentina End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
- Middle East and Africa
  - Middle East and Africa Service Outlook (Revenue in USD Million, 2018 - 2030)
    - Biomarker Assay Development & Validation
    - Flow Cytometry
    - Others
  - Middle East and Africa Application Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology
    - Drug Discovery & Development
    - Others
  - Middle East and Africa Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Molecular Biomarkers
    - Cellular Biomarkers
  - Middle East and Africa End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Pharmaceutical and Biotechnology Companies
    - Research Institutes
    - CROs
  - South Africa
    - South Africa Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - South Africa Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - South Africa Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - South Africa End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Saudi Arabia
    - Saudi Arabia Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Saudi Arabia Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Saudi Arabia Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Saudi Arabia End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - UAE
    - UAE Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - UAE Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - UAE Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - UAE End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Kuwait
    - Kuwait Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Kuwait Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Kuwait Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Kuwait End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs
  - Israel
    - Israel Service Outlook (Revenue in USD Million, 2018 - 2030)
      - Biomarker Assay Development & Validation
      - Flow Cytometry
      - Others
    - Israel Application Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology
      - Drug Discovery & Development
      - Others
    - Israel Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Molecular Biomarkers
      - Cellular Biomarkers
    - Israel End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Pharmaceutical and Biotechnology Companies
      - Research Institutes
      - CROs

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Quantitative Analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.